The U.S. Food and Drug Administration (FDA) is seeking proposals for the acquisition of an isolator to support sterility testing at its New York Laboratory Medical Products (NYLMP). The isolator must meet specific technical specifications, including a modular design, built-in bio-decontamination features, and necessary technical integrations to comply with FDA standards, addressing the increased demand on existing resources. This procurement is crucial for enhancing analytical capabilities, improving workflow, and ensuring adherence to quality standards in laboratory operations. Proposals are due electronically by September 17, 2024, at 10:00 a.m. (EST), and interested parties should contact Nina Montgomery at nina.montgomery@fda.hhs.gov for further information.